中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

261 records (took 0.028 seconds)

    DUAL VARIABLE DOMAIN IMMUNOGLOBIN AND USES THEREOF
    91.
    发明专利
    DUAL VARIABLE DOMAIN IMMUNOGLOBIN AND USES THEREOF 未知

    公开(公告)号：NZ597168A

    公开(公告)日：2013-07-26

    申请号：NZ59716806

    申请日：2006-08-18

    Applicant: ABBOTT LAB

    Inventor： WU CHENGBIN ,  GHAYUR TARIQ ,  DIXON RICHARD W ,  SALFELD JOCHEN G

    IPC: A61K38/00 ,  A61K31/192 ,  A61K31/343 ,  A61K31/365 ,  A61K31/4152 ,  A61K31/445 ,  A61K31/496 ,  A61K31/551 ,  A61K31/60 ,  A61K39/395 ,  A61K49/00 ,  A61K49/14 ,  A61K49/16

    Abstract: 597168 DUAL VARIABLE DOMAIN IMMUNOGLOBIN AND USES THEREOF Provided is a binding protein comprising first and second polypeptide chains, wherein said first polypeptide chain comprises VD1-(X1)n-VD2-C-(X2)n, wherein VD1 is a first immunoglobulin heavy chain variable domain, VD2 is a second immunoglobulin heavy chain variable domain, C is an immunoglobulin constant domain, X1 is a linker with the proviso that it is not an immunoglobulin constant domain, and X2 is an Fc region; and said second polypeptide chain comprises VD1-(X1)n-VD2-C-(X2)n, wherein VD1 is a first immunoglobulin light chain variable domain, VD2 is a second immunoglobulin light chain variable domain, C is an immunoglobulin constant domain, X1 is a linker with the proviso that it is not an immunoglobulin constant domain, and X2 is an Fc region; wherein n is 0 or 1; and wherein the first and second polypeptide chains form two functional antigen binding sites.

    TNF-alpha binding proteins
    94.
    发明专利
    TNF-alpha binding proteins 未知

    公开(公告)号：AU2011338313A1

    公开(公告)日：2013-05-02

    申请号：AU2011338313

    申请日：2011-12-08

    Applicant: ABBOTT GMBH & CO KG ,  ABBOTT LAB

    Inventor： HSIEH CHUNG-MING ,  GOODREAU CARRIE ,  GHAYUR TARIQ ,  MOELLER ACHIM ,  BOSE SAHANA

    IPC: C12P21/06

    Abstract: TNF-α binding proteins, including chimeric, CDR-grafted, and humanized antibodies that bind TNF-α are provided. Binding proteins have high affinity for TNF-α and neutralize TNF-α activity. A binding protein can be a full-length antibody or a TNF-α-binding portion thereof. Methods of making and methods of using the binding proteins are also described. The TNF-α binding proteins are useful for detecting TNF-α and for inhibiting TNF-α activity, including in a human subject suffering from a disease or disorder in which TNF-α activity is detrimental.

    METODOS DE TRATAMIENTO CON INHIBIDORES SELECTIVOS DE BCL-2
    95.
    发明专利
    METODOS DE TRATAMIENTO CON INHIBIDORES SELECTIVOS DE BCL-2 未知

    公开(公告)号：AR083946A1

    公开(公告)日：2013-04-10

    申请号：ARP110104338

    申请日：2011-11-22

    Applicant: ABBOTT LAB

    Inventor： GHAYUR TARIQ ,  PERPER STUART ,  ELMORE STEVEN ,  SOUERS ANDREW ,  WANG LICHUN

    IPC: A61K31/44 ,  A61K31/444 ,  A61K31/496 ,  A61P37/00

    Abstract: Métodos de tratamiento de lupus eritematoso sistémico, nefritis lúpica o síndrome de Sjogren con compuestos que inhiben selectivamente la actividad de las proteínas anti apoptóticas BcI 2.Reivindicación 2: El método de la reivindicación 1, caracterizado porque el inhibidor selectivo de BcI-2 es un compuesto de fórmula (1), donde A1 es N o CH; B1 es OR1 o NHR1; Y1 es CN, NO2, CF3, F o Cl; R1 es (CH2)nR2; R2 es cicloalquilo o heterociclilo; donde los grupos heterociclilo y cicloalquilo están opcionalmente sustituidos con uno o más sustituyentes seleccionados en forma independiente entre R4, OR4, OH, CN, o F; R3 es heteroarilo; donde el grupo heteroarilo está opcionalmente sustituido con uno o más sustituyentes seleccionados en forma independiente entre NH2, Cl, o F; R4 es alquilo, cicloalquilo, heterociclilo, o espiroheterociclilo; donde el grupo alquilo está opcionalmente sustituido con uno o más F; R5 es deuterio; cada R6 se selecciona en forma independiente entre CH3, espirociclopropilo y OH; m es 0, 1, 2, 3, 4, 5 ó 6; n es 0 ó 1; y p es 0, 1 ó 2; o una sal farmacéuticamente aceptable del mismo.

    DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF
    96.
    发明专利
    DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF 未知

    公开(公告)号：NZ588554A

    公开(公告)日：2013-03-28

    申请号：NZ58855409

    申请日：2009-04-28

    Applicant: ABBOTT LAB

    Inventor： GHAYUR TARIQ ,  MORGAN-LAPPE SUSAN E ,  REILLY EDWARD B ,  KINGSBURY GILLIAN A ,  PHILLIPS ANDREW ,  WANG JIEYI ,  BELL RANDY L ,  NORVELL SUZANNE M ,  LI YINGCHUN ,  LIU JUNJIAN ,  YING HUA

    IPC: A61K39/00

    Abstract: Disclosed is a binding protein comprising first and second polypeptide chains, each independently comprising VD1-(X1)n-VD2-C-(X2)n, wherein VD1 is a first variable domain; VD2 is a second variable domain; C is a constant domain; X1 is a linker with the proviso that it is not CH1; X2 is an Fc region; n is 0 or 1. Furthermore, the VD1 domains on the first and second polypeptide chains form a first functional target binding site and the VD2 domains on the first and second polypeptide chains form a second functional target binding site and are as defined in the specification. The disclosed binding protein is capable of binding to VEGF with an EC50 of at most about 28.25 nM, as measured by direct bind ELISA, and/or the binding protein is capable of binding to DLL4 with an EC50 of at most about 2.12nM, as measured by direct bind ELISA.

    DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF
    99.
    发明专利
    DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF 未知

    公开(公告)号：NZ589434A

    公开(公告)日：2012-11-30

    申请号：NZ58943409

    申请日：2009-06-03

    Applicant: ABBOTT LAB

    Inventor： GHAYUR TARIQ ,  ISAKSON PETER C

    IPC: C07K16/20 ,  C07K16/46 ,  C12P21/08

    Abstract: Provides is a binding protein comprising first and second polypeptide chains, wherein said first polypeptide chain comprises a first VD1-(X1)n-VD2-C-(X2)n, wherein VD is a first heavy chain variable domain; VD2 is a second heavy chain variable domain; C is a heavy chain constant domain; XI is a linker with the proviso that it is not CHI; X2 is an Fc region; n is 0 or 1; and wherein said second polypeptide chain comprises a second VD1-(X1)n-VD2-C-(X2)n, wherein VD 1 is a first light chain variable domain; VD2 is a second light chain variable domain; C is a light chain constant domain; XI is a linker with the proviso that it is not CHI; X2 does not comprise an Fc region; nis 0 or 1; and wherein the binding protein binds TNF and IL-17A, wherein the heavy and light chain six CDRs have defined sequences. The antibodies can be used for various diseases, including immunological conditions and cancers.

Patent Agency Ranking